Ocular immune privilege: Therapeutic opportunities from an experiment of nature

Nature Reviews Immunology

Volumn 3, Issue 11, 2003, Pages 879-889

  Streilein, J Wayne ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CALCITONIN GENE RELATED PEPTIDE; CD59 ANTIGEN; CYTOKINE; DECAY ACCELERATING FACTOR; FAS LIGAND; INTERLEUKIN 1 RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MEMBRANE COFACTOR PROTEIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA2; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLOGRAFT; AQUEOUS HUMOR; AUTOIMMUNE DISEASE; BLINDNESS; CORNEA; CORNEA TRANSPLANTATION; EYE; EYE DISEASE; EYE INFLAMMATION; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; VISION; VISUAL IMPAIRMENT;

EID: 0242636366     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1224     Document Type: Review

References (120)

1. Medawar, P. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 129, 58-69 (1948).
2. Billingham, R. E. & Boswell, T. Studies on the problem of corneal homografts. Proc. R. Soc. Lond. 141, 392-406 (1953).
3. Barker, C. F. & Billinghamm, R. E. Immunologically privileged sites. Adv. Immunol. 25, 1-54 (1977).
4. Streilein, J. W. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr. Opin. Immunol. 5, 428-432 (1993).
5. Streilein, J. W. News and Views. Unraveling immune privilege. Science 270, 1158-1159 (1995).
6. Streilein, J. W. in Immune Responses and the Eye Chemical Immunology 73 (ed. Streilein, J. W.) 11-38 (Karger AG, Basel, 1999). Ocular immune privilege is defined historically in the context of the concept of regional immunity.
7. Niederkorn, J. Y. Immune privilege in the anterior chamber of the eye. Crit. Rev. Immunol. 22, 13-46 (2002).
8. Streilein, J. W. & Stein-Streilein, J. Does innate immune privilege exist? J. Leukocyte Biology 67, 479-487 (2000).
9. Niederkorn, J., Streilein, J. W. & Shadduck, J. A. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest. Ophthalmol. Vis. Sci. 20, 355-363 (1980).
10. Jiang, L. Q., Jorquera, M. & Streilein, J. W. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest. Ophthalmol. Vis. Sci. 34, 3347-3354 (1993).
11. Wenkel, H., Chen, P. W., Ksander, B. R. & Streilein, J. W. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space. Invest. Ophthalmol. Vis. Sci. 40, 3202-3208 (1999).
12. Apte, R. S., Mayhew, E. & Niederkorn, J. Y. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38, 1277-1282 (1997).
13. Hori, J., Joyce, N. & Streilein, J. W. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest. Ophthalmol. Vis. Sci. 41, 443-452 (2000).
14. Hori, J., Joyce, N. C. & Streilein, J. W. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest. Ophthalmol. Vis. Sci. 41, 3032-3042 (2000).
15. Wenkel, H. & Streilein, J. W. Evidence that retinal pigment epithelium functions as an immune privileged tissue. Invest. Ophthalmol. Vis. Sci. 41, 3467-3473 (2000).
16. Ng, T. F., Osawa, H., Hori, J., Young, M. J. & Streilein, J. W. Allogeneic neonatal neuronal retina grafts display partial immune privilege in the subcapsular space of the kidney. J. Immunol. 169, 5601-5606 (2002).
17. Matsubara, M. & Tanishima, T. Wound-healing of corneal endothelium in monkey: an autoradiographic study. Jpn. J. Ophthalmol. 27, 444-450 (1983).
18. So, W. F. & Aguayo, A. J. Lengthy regrowth of cut axons from ganglion cells after peripheral nerve transplantation into the retina of adult rats. Brain. Res. 328, 349-354 (1985).
19. Streilein, J. W. in Immune Responses and the Eye Chemical Immunology 73 (ed. Streilein, J. W.) 186-206 (Karger AG, Basel, 1999). A review of the role of immune privilege in the high rate of acceptance of corneal transplants without immunosuppression, including an analysis of the immunopathogenic mechanisms that can destroy cornea grafts in diseased eyes.
20. Niederkorn, J. Y. Immunology and immunomodulation of corneal transplantation. Int. Rev. Immunol. 21, 173-196 (2002).
21. Wang, H. M., Kaplan, H. J., Chan, W. C. & Johnson, M. The distribution and ontogeny of MHC antigens in murine ocular tissues. Invest. Ophthalmol. Vis. Sci. 28, 1383-1389 (1987).
22. Abi-Hanna, D., Wakefield, D. & Watkins, S. HLA antigens in ocular tissues. Transplantation 45, 610-613 (1998).
23. Nicholls, S. M., Bradley, B. B. & Easty, D. L. Effect of mismatches of major histocompatibility complex and minor antigens on corneal graft rejection. Invest. Ophthalmol. Vis. Sci. 32, 2729-2734 (1991).
24. Sonoda, Y. & Streilein, J. W. Orthotopic corneal transplantation in mice. Evidence that the immunogenetic rules of rejection do not apply. Transplantation 54, 694-703 (1992).
25. Joo, C. K., Repose, J. S. & Stuart, P. M. T-cell mediated responses in a murine model of orthotopic corneal transplantation. Invest. Ophthalmol. Vis. Sci. 36, 1530-1540 (1995).
26. He, Y. G., Ross, J. & Niederkorn, J. Y. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest. Ophthalmol. Vis. Sci. 32, 2723-2728 (1991).
27. Ayliffe, W., Alam, Y., Bell, E. B., McLeod, D. & Hutchinson, I. V. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br. J. Ophthalmol. 76, 602-606 (1992).
28. + T cells in immunobiology of orthotopic corneal transplants in mice. Invest. Ophthalmol. Vis. Sci. 40, 2614-2521 (1999).
29. Yamada, J., Ksander, B. R. & Streilein, J. W. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest. Ophthalmol. Vis. Sci. 42, 386-392 (2001).
30. Streilein, J. W., Toews, G. B. & Bergstresser, P. R. Corneal allografts fail to express la antigens. Nature 282, 326-327 (1979).
31. Hamrah, P., Liu, Y., Zhang, Q. & Dana, M. R. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest. Ophthalmol. Vis. Sci. 44, 581-589 (2003). This paper shows the unexpected finding that MHC class-II-negative bone-marrow-derived cells are well represented in the corneal stroma, and that they include three different populations (macrophages, precursor and immature dendritic cells).
32. Shoskes, D. A. & Wood, K. J. Indirect presentation of MHC antigens in transplantation. Immunol. Today 13, 32-38 (1994).
33. Lee, R. S., Grusby, M. J., Glimcher, L. H., Winn, J. H. & Auchincloss, H. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J. Exp. Med. 179, 865-872 (1994).
34. Lafferty, K. J., Prowse, S. J., Simeonovic, C. J. & Warren, H. S. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1, 142-173 (1983).
35. Cursiefen, C., Chen, L., Dana, M. R. & Streilein, J. W. Corneal lymphangiogenesis: evidence, mechanisms and implications for corneal transplant immunology. Comea 22, 273-281 (2003).
36. Haskova, Z., Arancibia-Carcamo, C. V., Christianson, G. J., Roopenian, D. C. & Ksander, B. R. in Uveitis in the Third Millenium (eds Dodds, E. M. & Couto, C. A.) 7-10 (Elsevier Science, Amsterdam, 2000).
37. + T cells are critical for corneal, but not skin, allograft rejection. Transplantation 69, 483-487 (2000).
38. Figueiredo, F. C., Pendergrast, D. G., Shang, L., Easty, D. L. & Nicholls, S. M. An improved method for examining the corneal endothelium during graft rejection in the rat. Exp. Eye. Res. 67, 625-630 (1998).
39. Streilein, J. W., Arancibia-Carcamo, C. & Osawa, H. in Adequate HLA Matching in Keratoplasty Developmental Ophthalmology Vol. 36 (ed. Sundmacher, R.) 74-88 (Karger AG, Basel, 2003).
40. Hori, J. & Streilein, J. W. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest. Ophthalmol. Vis. Sci. 42, 720-726 (2001).
41. Sano, Y., Ksander, B. R. & Streilein, J. W. Fate of orthotopic corneal allografts in eyes that cannot support ACAID induction. Invest. Ophthalmol. Vis. Sci. 36, 2176-2185 (1995). This paper shows how immune privilege in the eye is disrupted by experimental manipulations of the cornea.
42. Sano, Y., Ksander, B. R. & Streilein, J. W. Murine orthotopic corneal transplantation in 'high-risk' eyes. Rejection is dictated primarily by weak rather than strong alloantigens. Invest. Ophthalmol. Vis. Sci. 38, 1130-1138 (1997).
43. Sano, Y., Streilein, J. W. & Ksander, B. R. Detection of minor alloantigen-specific cytotoxic T cells after rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized exclusively via the 'indirect pathway'. Transplantation 68, 963-970 (1999).
44. Sano, Y., Ksander, B. R. & Streilein, J. W. Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T cell allorecognition. Invest. Ophthalmol. Vis. Sci. 41, 1422-1431 (2000).
45. Liu, Y., Hamrah, P., Zhang, Q., Taylor, A. W. & Dana, M. R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J. Exp. Med. 195, 259-268 (2002). The bone-marrow-derived cells that are unexpectedly present in the cornea were shown in this study to migrate through lymphatics to draining cervical lymph nodes where they come to rest in T-cell-dependent areas of the parafollicular cortex.
46. 1 lymphocyte-induced immune deviation. J. Immunol. 118, 809-814 (1977).
47. 1 lymphocyte induced immune deviation. J. Immunol. 120, 689-693 (1978).
48. Streilein, J. W., Niederkorn, J. Y. & Shadduck, J. A. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J. Exp. Med 152, 1121-1125 (1980).
49. Ksander, B. R. & Streilein, J. W. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors. I. Quantitative and qualitative analysis of cytotoxic precursor and effector cells. Invest. Ophthalmol. Vis. Sci. 30, 323-329 (1989).
50. 2a-secreting B-cells. Immunology 71, 566-572 (1990).
51. Jiang, L. Q. & Streilein, J. W. Immune privilege extended to allogeneic tumor cells in the vitreous cavity. Invest. Ophthalmol. Vis. Sci. 32, 224-228 (1991).
52. Wenkel, H. & Streilein, J. W. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest. Ophthalmol. Vis. Sci. 39, 1823-1834 (1998).
53. Wilbanks, G. A. & Streilein, J. W. Studies on the induction of anterior chamber associated immune deviation (ACAID). I. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J. Immunol. 146, 2610-2617 (1991).
54. Wilbanks, G. A., Mammolenti, M. M. & Streilein, J. W. Studies on the induction of anterior chamber associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood borne signals that induce ACAID. J. Immunol. 146, 3018-3024 (1991).
55. Wilbanks, G. & Streilein, J. W. Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Regional Immunol. 4, 139-137 (1992).
56. Sonoda, K. H., Exley, M., Snapper, S., Balk, S. P. & Stein-Streilein, J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190, 1215-1226 (1999). This paper not only shows that CD1-reactive natural-killer T cells are required for anterior-chamber-associated immune deviation (ACAID), but it is also the first example of a physiological function for these recently appreciated cells.
57. Faunce, D. E., Sonoda, K. H. & Stein-Streilein, J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 166, 313-321 (2001).
58. Takeuchi, M., Alard, P. & Streilein, J. W. TGF-β promotes immune deviation by altering accessory signals of antigen presenting cells. J. Immunol. 160, 1589-1597 (1998).
59. Sonoda, K. H. et al. NKT cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J. Immunol. 166, 42-50 (2001).
60. + T cells to the spleen during the generation of regulatory T cells in tolerance. J. Immunol. 169, 31-38 (2002). The clusters of interacting cells that accumulate in the marginal zone of the spleen during ACAID are assembled by chemokines that are secreted by the early arriving cells. This paper gives insight into how immune-cell interactions are orchestrated in tolerance induction.
61. D'Orazio, T. J. & Niederkorn, J. Y. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology 95, 47-55 (1998).
62. Sonoda, K. H. & Stein-Streilein, J. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur. J. Immunol. 32, 848-857 (2002).
63. Skelsey, M. E., Mellon, J. & Niederkorn, J. Y. γδ T cells are needed for ocular immune privilege and corneal graft survival. J. Immunol. 166, 4327-4333 (2001).
64. + CTL responses. Invest. Ophthalmol. Vis. Sci. 43, 3473-3479 (2002).
65. D'Orazio, T. J., Mayhew, E. & Niederkorn, J. Y. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J. Immunol. 166, 26-32 (2001).
66. Niederkorn, J. Y. & Streilein, J. W. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed type hypersensitivity but normal cytotoxic T lymphocyte responses J. Immunol. 131, 2670-2674 (1983).
67. Wilbanks, G. A. & Streilein, J. W. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology 71, 383-389 (1990).
68. Niederkorn, J. Y. in Immune Responses and the Eye Chemical Immunology Vol. 73 (ed. J. W. Streilein) 59-71 (Karger AG, Basel, 1999).
69. Stein-Streilein, J. & Streilein, J. W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int. Rev. Immunol. 21, 123-152 (2002).
70. Streilein, J. W., Masli, S., Takeuchi, M. & Kezuka, T. The eye's view of antigen presentation. Human Immunol. 63, 435-443 (2002). The authors give a detailed description and synthesis of recent knowledge about the cellular and molecular mechanisms that give rise to eye-derived tolerance.
71. Wilbanks, G. A., Mammolenti, M. M. & Streilein, J. W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-β. Eur. J. Immunol. 22, 165-173 (1992)
72. Hara, Y., Caspi, R. R., Wiggert, B., Dorf, M. & Streilein, J. W. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J. Immunol. 149, 1531-1538 (1992).
73. Masli, S. & Streilein, J. W. Expression of thrombospondin in TGFβ-treated antigen presenting cells and its relevance to their immune deviation-promoting properties. J. Immunol. 1168, 2264-2273 (2002). Thrombospondin, not generally regarded as being immunomodulatory, is identified in this study as a central player in the complex process by which eye-derived antigens give rise to ACAID.
74. Sano, Y., Okamoto, S. & Streilein, J. W. Induction of donor-specific ACAID can prolong orthotopic corneal allograft survival in 'high-risk' eyes. Curr. Eye. Res. 16, 1171-1174 (1997).
75. Hara, Y. et al. Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber associated immune deviation with interphotoreceptor retinoid binding protein. J. Immunol. 148, 1685-1692 (1992).
76. H2-dependent pulmonary pathology. J. Immunol. 169, 84-89 (2002).
77. Kezuka, T. & Streilein, J. W. Analysis of in vivo regulatory properties of T cells activated in vitro by TGFβ2-treated antigen presenting cells. Invest. Ophthalmol. Vis. Sci. 41, 1410-1421 (2000).
78. + T cells similar to those found in mice with anterior chamber associated immune deviation. Invest. Ophthalmol. Vis. Sci. 41, 1803-1811 (2000).
79. Wang, Y. et al. Direct thymic involvement in anterior chamber-associated immune deviation. J. Immunol. 158, 2150-2155 (1997).
80. Wang, T., Goldschneider, I., O'Rourke, J. & Cone, R. E. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J. Leukoc. Biol. 69, 741-746 (2001).
81. Taylor, A. W. in Immune Response and the Eye Chemical Immunology Vol. 73 (ed. Streilein, J. W.) 72-89 (Karger, Basel, 1999). This paper provides an in-depth examination of the many factors that are present in intraocular fluids and how these factors confer these fluids with their immunosuppressive and anti-inflammatory properties.
82. Kaiser, C. J., Ksander, B. R. & Streilein, J. W. Inhibition of lymphocyte proliferation by aqueous humor. Regional Immunol. 2, 42-49 (1989).
83. Taylor, A. W., Streilein, J. W. & Cousins, S. W. Vasoactive intestinal peptide (VIP) contributes to the immunosuppressive activity of normal aqueous humor. J. Immunol. 153, 1080-1086 (1994).
84. Taylor, A. W. & Yee, D. G. Somatostatin is an immunosuppressive factor in aqueous humor. Invest. Ophthalmol Vis. Sci. 44, 2644-2649 (2003).
85. Taylor, A. W., Streilein, J. W. & Cousins, S. W. Identification α-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr. Eye. Res. 11, 1199-1206 (1992).
86. Namba, K., Kataichi, N., Nishida, T. & Taylor, A. W. Induction of regulatory T cells by the immunomodulating cytokines α -melanocyte-stimulating hormone and transforming growth factor-β2. J. Leukoc. Biol. 72, 946-952 (2002). Exposure to aqueous humor inhibits T-cell activation. This paper indicates that as this inhibition is proceeding, the T cells acquire regulatory functions, and they can act systemically to suppress autoimmune disease of the eye.
87. Taylor, A. W., Yee, D. G. & Streilein, J. W. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest. Ophthalmol. Vis. Sci. 39, 1372-1378 (1998).
88. Apte, R. S., Sinha, D., Mayhew, E., Wistow, G. L. & Niederkorn, J. Y. Role of macrophage migration inhibitory factor in inhibiting NK cell activity. J. Immunol. 160, 5693-5696 (1998).
89. Gregory, M. S. et al. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169, 2727-2735 (2002).
90. Goslings, W. R. O. et al. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest. Ophthalmol. Vis. Sci. 39, 989-995 (1998).
91. Streilein, J. W., Ohta, K., Mo, J. S. & Taylor, A. W. Ocular immune privilege and the impact of intraocular inflammation. DNA Cell Biol. 21, 453-2002 (2002).
92. Ohta, K., Wiggert, B., Yamagami, S., Taylor, A. W. & Streilein, J. W. Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J. Immunol. 164, 1185-1192 (2000).
93. Ohta, K., Yamagami, S., Taylor, A. W. & Streilein, J. W. IL-6 antagonizes TGF-β and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 41, 2591-2599 (2000).
94. Mo, J. S. & Streilein, J. W. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur. J. Immunol. 31, 3806-3815 (2001).
95. Ferguson, T. A., Green, D. R. & Griffith, T. S. Cell death and immune privilege. Int. Rev. Immunol. 21, 153-172 (2003).
96. Griffith, T., Brunner, T., Fletcher, S. M., Green, D. R. & Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
97. Stuart, P. M. et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99, 396-402 (1997). The discovery of constitutive expression of CD95 ligand by ocular parenchymal cells offers the first example of a molecule originally linked to immune system function that is unexpectedly expressed by an immune-privileged tissue, and contributes to the capacity of that tissue to avoid destruction by immune T cells.
98. Yamagami, S., Kawashima, H., Tsuru, T. & Gregerson, D. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 64, 1107-1111 (1997).
99. Bora, N. S., Gobleman, C. I., Atkinson, J. P., Pepose, J. S. & Kaplan, H. J. Differential expression of the complement regulatory proteins in the human eye. Invest. Ophthalmol. Vis. Sci. 34, 3579-3584 (1993).
100. Bora, H. S. et al. in Advances in Ocular Imunolology (eds Nussenblatt, R. B., Whitcup, S. M., Caspi, R. R. & Gery, I.) 83-86 (Amsterdam, Elsevier, 1994).
101. Sohn, J. H., Kaplan, H. J., Suk, H. J., Bora, P. S. & Bora, N. S. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 41, 3492-3502 (2000). This is the first definitive report to document that the constitutive expression of membrane-bound complement inhibitors in the eye acts to suppress spontaneous inflammation.
102. Sugita, S. & Streilein, J. W. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to CTLA-4. J. Exp. Med. 198, 161-171 (2003). This paper confirms an immune-privilege strategy of hijacking molecules that are normally used during immune-cell activation (CD86), and expressing them on ocular parenchymal cells where they suppress T-cell activation, thereby preventing inflammation.
103. Yoshida, M., Kezuka, T. & Streilein, J. W. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 2. Generation of regulatory T cells that suppress bystander T cells via TGFβ. Invest. Ophthalmol. Vis. Sci. 41, 3862-3870 (2000).
104. Kosiewicz, M. M. et al. Imposing deviant immunity on the presensitized state. J. Immunol. 153, 2962 (1994).
105. Hori, J. & Streilein, J. W. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest. Ophthalmol. Vis. Sci. 42, 720-726 (2001).
106. Hori, J. & Streilein, J. W. Survival in high-risk eyes of epithelium-deprived orthotopic corneal allografts reconstituted in vitro with syngeneic epithelium. Invest. Ophthalmol. Vis. Sci. 44, 658-664 (2003).
107. Kang, S. M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 7, 738-743 (1997).
108. Suda, Z., Hashimoto, H., Tanaka, M., Ochi, T. & Nagata, S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186, 2045-2050 (1997).
109. Hohlbaum, A. M., Moe, S. & Marshak-Rothstein, A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191, 1209-1220 (2000).
110. Sano, Y. et al. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege. Exp. Eye Res. 75, 475-483 (2002).
111. Niederkorn, J. Y., Chiang, E. Y., Ungchusri, T. & Stroynowski, I. Expression of a nonclassical MHC class Ib molecule in the eye. Transplantation 68, 1790-1799 (1999).
112. Streilein, J. W., Dana, M. R. & Ksander, B. R. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol. Today 18, 443-449 (1997).
113. Pearlman, E. et al. Interleukin 4 and T helper type 2 cells are required for development of experimental onchocercal keratitis (river blindness). J. Exp. Med. 182, 931-940 (1995).
114. Sohn, J. H. et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nature Med. 9, 206-212 (2003). Constitutive activation of complement at low levels in the eye is reported here to be essential for the induction of ACAID when antigen is introduced into the anterior chamber of the eye. The idea that activation of innate immunity leads to eye-derived tolerance is new and provocative.
115. Cousins, S. W., McCabe, M. M., Danielpour, D. & Streilein, J. W. Identification of transforming growth factor-β as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 32, 2201-2211 (1991).
116. Sheibani, N., Sorenson, C. M., Cornelius, L. A. & Frazier, W. A. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem. Biophys. Res. Commun. 267, 257-268 (2000).
117. Kennedy, M. C., Rosenbaum, J. T. & Brown, J. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J. Clin. Invest. 95, 82-88 (1995).
118. Sohn, J. H., Kaplan, H. J., Suk, H. J., Bora, P. S. & Bora, N. S. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest. Ophthalmol. Vis. Sci. 41, 4195-4202 (2000).
119. Sugita, S. et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br. J. Ophthalmol. 84, 1130-1134 (2000).
120. Ishida, K., Panjwani, N., Cao, Z. & Streilein, J. W. Participation of pigment epithelium in ocular immune privilege 3. Galectin-1 contributes to immunosuppressive properties of retinal pigment epithelium. Ocular Immun. Inflamm. (in the press).